Research Article

ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE

Volume: 27 Number: 3 December 25, 2025
TR EN

ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE

Abstract

Objective: This study aimed to present the procedure features, technical success, short-term patency rates, and complications in patients who underwent endovascular treatment due to native arteriovenous fistula failure or insufficient dialysis. Material and Methods: Between 2012 and 2018, 114 procedures were performed on 96 patients (54 males, 42 females) aged 26-86 years (mean: 58.5 years) who were treated percutaneously for native dialysis fistula dysfunction. AVF characteristics, stenosis/occlusion location, balloon or stent size, technical success, complications, and primary patency rates at 6 and 12 months were recorded. Results: Radiocephalic fistulas (83.4%) were the most common type treated. Percutaneous transluminal angioplasty (PTA) was performed alone (77.2%) or with other procedures in all patients with stenotic or occluded segments. A stent was placed in 5 patients due to residual stenosis. t-PA infusion via a thrombolytic catheter was performed in 16 patients, and mechanical aspiration in 5 patients where PTA alone would not suffice due to thrombus burden. The technical success rate of the endovascular treatments was 92.7%, with a complication rate of 3.1%. The median primary patency duration was 187 days, with primary patency rates of 67.5% and 58.5% at 6 and 12 months, respectively. Conclusion: AVF is the first choice of vascular access in hemodialysis patients. However, most AVFs require endovascular intervention due to stenosis and/or occlusions developing in one or more segments over time. Interventional procedures can be performed effectively and safely, with high technical success and low complication rates in the treatment of native AVF dysfunction.

Keywords

References

  1. Taurisano M, Mancini A, Cortese C, Napoli M. Endovascular tools for vascular access stenosis: Flow-chart proposal. J Vasc Access. 2025;26(1):30-39.
  2. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2021;77(4):1-164.
  3. MacRae JM, Dipchand C, Oliver M, et al. Arteriovenous access failure, stenosis, and thrombosis. Can J Kidney Health Dis. 2016;3:2054358116669126.
  4. Rajan DK, Bunston S, Misra S, Pinto R, Lok CE. Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty--are there clinical predictors of patency?. Radiology. 2004;232(2):508-515.
  5. Turmel-Rodrigues L, Pengloan J, Baudin S, et al. Treatment of stenosis and thrombosis in haemodialysis fistulas and grafts by interventional radiology. Nephrol Dial Transplant. 2000;15(12):2029-2036.
  6. Clark TW, Hirsch DA, Jindal KJ, Veugelers PJ, LeBlanc J. Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas. J Vasc Interv Radiol. 2002;13(1):51-59.
  7. Aktas A, Bozkurt A, Aktas B, Kirbas I. Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting postprocedural fistula patency. Diagn Interv Radiol. 2015;21(2):160-166.
  8. Bizarro P, Coentrão L, Ribeiro C, Neto R, Pestana M. Endovascular treatment of thrombosed dialysis fistulae: A cumulative cost analysis. Catheter Cardiovasc Interv. 2011;77(7):1065-1070.

Details

Primary Language

English

Subjects

Health Services and Systems (Other)

Journal Section

Research Article

Publication Date

December 25, 2025

Submission Date

July 12, 2025

Acceptance Date

July 22, 2025

Published in Issue

Year 2025 Volume: 27 Number: 3

APA
Durmaz, H. (2025). ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE. The Journal of Kırıkkale University Faculty of Medicine, 27(3), 355-359. https://doi.org/10.24938/kutfd.1740849
AMA
1.Durmaz H. ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE. Kırıkkale Uni Med J. 2025;27(3):355-359. doi:10.24938/kutfd.1740849
Chicago
Durmaz, Hasanali. 2025. “ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE”. The Journal of Kırıkkale University Faculty of Medicine 27 (3): 355-59. https://doi.org/10.24938/kutfd.1740849.
EndNote
Durmaz H (December 1, 2025) ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE. The Journal of Kırıkkale University Faculty of Medicine 27 3 355–359.
IEEE
[1]H. Durmaz, “ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE”, Kırıkkale Uni Med J, vol. 27, no. 3, pp. 355–359, Dec. 2025, doi: 10.24938/kutfd.1740849.
ISNAD
Durmaz, Hasanali. “ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE”. The Journal of Kırıkkale University Faculty of Medicine 27/3 (December 1, 2025): 355-359. https://doi.org/10.24938/kutfd.1740849.
JAMA
1.Durmaz H. ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE. Kırıkkale Uni Med J. 2025;27:355–359.
MLA
Durmaz, Hasanali. “ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE”. The Journal of Kırıkkale University Faculty of Medicine, vol. 27, no. 3, Dec. 2025, pp. 355-9, doi:10.24938/kutfd.1740849.
Vancouver
1.Hasanali Durmaz. ENDOVASCULAR TREATMENT IN NATIVE HEMODIALYSIS AV FISTULA DYSFUNCTIONS, A SINGLE-CENTER EXPERIENCE. Kırıkkale Uni Med J. 2025 Dec. 1;27(3):355-9. doi:10.24938/kutfd.1740849

This Journal is a Publication of Kırıkkale University Faculty of Medicine.